VACCINE ADJUVANT MARKET ANALYSIS

Vaccine Adjuvant Market, By Type (Mineral Salt-based Adjuvant, Tensoactive Adjuvants, Adjuvant Emulsions, Liposome Adjuvants, Carbohydrate Adjuvants, Bacteria-derived Adjuvants, Virus-like Particles (VLP), and Other Types), By Usage (Active Immunostimulants, Carriers, and Vehicle Adjuvants), By Disease Type (Infectious Disease and Cancer), By Application (Research Applications and Commercial Applications), and By Geography (North America, Europe, Asia Pacific, Middle East and Africa, and Rest of World)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published In : Jan 2023
Code : CMI1731
Pages :169
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

Global Vaccine Adjuvant Market: Key Developments

In May 2022, China’s National Medical Products Administration (NMPA) granted approval for GlaxoSmithKline’s (GSK) two-dose vaccine schedule, Cervarix, in girls between the ages of nine to 14 years to prevent cervical cancer. Cervarix is a recombinant, non-infectious, AS04-adjuvanted HPV bivalent (types 16, 18) vaccine.

In July 2021, Dynavax Technologies Corp. and Biological E. Limited (BE) executed a commercial supply agreement of Dynavax’s CpG 1018TM advanced adjuvant for use in BE’s subunit COVID- 19 vaccine candidate, CORBEVAX.

In September 2021, Novavax Inc. enrolled the first participant in its Phase 1/2 study, evaluating the safety and immunogenicity of a combination vaccine using Novavax’s seasonal influenza and COVID-19 vaccine. Clinical trial includes recombinant protein-based NVX-CoV2373 & NanoFlu vaccine candidates and patented saponin-based Matrix-M adjuvant in a single formulation.

In June 2021, Thermo Fisher Scientific entered an agreement with Moderna Inc., a biotechnology company involved in messenger RNA (mRNA) therapeutics and vaccines, for fill/finish sterile manufacturing services and supply packaging for Moderna’s COVID- 19 vaccine.